

## Comparison of the Clinical Result of Diverse $\beta$ -Blockers in Heart Failure Patients: A Systematic Review

Amalia Tri Utami<sup>1\*</sup>

<sup>1</sup>State University of Malang, Indonesia

\*Corresponding Author: Amalia Tri Utami

State University of Malang, Indonesia

Article History: | Received: 22.08.2022 | Accepted: 05.10.2022 | Published: 11.10.2022 |

**Abstract: Background:** Starting from the mid-late 90s,  $\beta$ -blockers have ended up as the therapy of choice for heart failure (HF).  $\beta$ -blockers act with important and reliable beneficial effects on survival and reduction of the manifestations of patients with heart failure (HF). In a placebo-controlled study conducted at that time,  $\beta$ -blockers have been recognized as necessary treatment in patients who are slowly but steadily. However, today there are many options for  $\beta$ -blockers. **Objective:** To provide a logical basis for the use of  $\beta$ -blockers for patients with heart failure and determine the most effective  $\beta$ -blockers. **Methods:** The authors made statistical associations, and calculated the different levels and risks that can distribute different blockers in heart failure patients. Studies were identified from Scopus, Science Direct, PubMed, and Google Scholar databases and then analyzed using Prism Chart 2020. **Results:** Carvedilol is a superior drug class against cardiac remodeling and consequent heart failure compared to other specific  $\beta$ -blockers. Some of its advantages include combining comprehensive blocking of all 3 adrenergic receptors, anti-apoptotic and anti-endothelin effects. **Conclusions:** Carvedilol is said to be the most effective heart drug to date, although many other side effects have been discovered. There needs to be a breakthrough in halal medicine for halal medicinal diseases when used by the Muslim community which is relatively safer and more comfortable to use.

**Keywords:**  $\beta$ -Blocker, Carvedilol, Heart Failure.

Copyright © 2022 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

### 1. INTRODUCTION

Recently,  $\beta$ -blockers have become one of the fastest growing options in the treatment of heart failure. It is because of their important and stable impact on survival and symptomatic reduction of heart failure (HF) in the extensive placebo-controlled studies conducted at that time;  $\beta$ -blockers have been recognized as mandatory treatment in patients with slowly stable, direct, and chronic HF [1-4]. In addition, in patients with LV damage and/or heart failure immediately after intense local myocardial necrosis, carvedilol also resulted in improved survival compared with placebo treatment [5, 6]. As a result, carvedilol, bisoprolol, metoprolol succinate, and nebivolol have been recognized for the treatment of continuous HF (NYHA II-IV) with either ischemic or non-ischemic concomitant use, which is used in the universal rule for the treatment of HF [7, 8]. Such a rule, however, does not address an important address for doctors: "which

beta blocker to use"? Are they all basically viable and equally enduring, or maybe one is more preferable for  $\beta$ -blockers as the treatment of continuous heart failure?

### 2. METHOD

All English-language articles from extensive randomized controlled clinical trials surveying the mortality benefit of beta-blockers in patients with heart failure are recognized to supply a logical method of reasoning for the utilization of beta-blockers in heart failure. The authors analyzed all reports from 2003 - 2022. Fundamental science studies were examined to provide a diagram of the physiological part of beta-blockers potential in heart failure. Finally, clinical guidelines for the treatment of patients with heart failure were evaluated to decide on current recommendations for the use of beta blockers in this disease.




Diagram 1: Literature Search Using Prism Chart 2020

### 3. RESULT

After searching the journals based on the inclusion and exclusion criteria that the author made. Furthermore, a journal study was carried out, and 10 research articles were obtained which were included in this systematic review (table 1).

### 4. DISCUSSION

#### Mechanism Action of β-Blocker Drugs

β-blockers decrease astute uncertain system activity through the blockade of adrenergic receptor subtypes, particularly β1, β2, and β3. β1 receptors are basically inside the heart and many of the valuable impacts of blockade consolidate bradycardia and made

strides in diastolic coronary filling time, lessened oxygen necessities, and a diminishment of renin, all invaluable in heart failure and myocardial ischemia [6-12]. β2 receptors are for the foremost portion found within the smooth muscle of blood vessels and the bronchial tree and prompting leads to broadening. β3 receptors are found in adipocytes and the heart, and bar by nonselective masters might contribute to their weight-increase and metabolic impacts [13]. β-blocker specificity implies to the drugs' more noticeable affection for β1 receptors over β2 at regular sedate levels, and so specificity for cardiac impacts, and nonspecific administrators that additionally piece β2 receptors reduce antihypertensive movement [14].

Table 1: Comparison of the Clinical Result of Diverse β-Blockers in Heart Failure Patients

Author	Origin	Method	Period	Result	Outcome
Keating GM, Jarvis B.	Adis International Limited, Mairangi Bay, New Zealand	Combined analysis of studies in the US Carvedilol Heart Failure Trials Program	2003	Carvedilol was for the most part well endured in patients with CHF. Unfavorable occasions related with the alpha- and beta-blocking impacts of the sedate happened more commonly with carvedilol than with fake treatment, though fake treatment beneficiaries were more likely to involvement compounding heart failure. In conclusion, carvedilol squares beta(1)-, beta(2)- and alpha(1)-adrenoceptors and features a special pharmacological profile.	In conclusion, carvedilol squares beta(1)-, beta(2)- and alpha(1)-adrenoceptors and features a special pharmacological profile. It is thought that extra properties of carvedilol (e.g. antioxidant and antiproliferative impacts) contribute to its useful impacts in CHF. Carvedilol moves forward ventricular work and decreases mortality and dreariness in patients with mellow to extreme CHF, and ought to be considered a standard treatment choice in this setting. Regulating carvedilol in expansion to ordinary treatment diminishes mortality and constricts myocardial renovating in patients with cleared out ventricular brokenness taking after intense MI. Additionally, mortality was altogether lower with carvedilol than with metoprolol.

Author	Origin	Method	Period	Result	Outcome
James E Udelson	Tufts University School of Medicine, Boston, Massachusetts, USA	Literature review	2004	Cleared-out ventricular (LV) remodeling has an imperative part in the movement of cardiovascular disease. An understanding of the method of LV remodeling has driven more prominent information on the pathophysiology of heart failure. Sedate treatments that moderate or turn around the remodeling preparation appear to have favorable normal history impacts in short-term and long-term treatment. Angiotensin-converting protein (Pro) inhibitors have been related to a noteworthy lessening in mortality, and the impact of beta-blockers on the remodeling preparation has presently been considered over much of the range of seriousness in patients with heart failure.	Beta-Blockade appears to include favorable and free impacts on the post-myocardial localized necrosis remodeling preparation over and over those of Pro inhibitors. A combination of both drugs shows the most noteworthy lessening in mortality (ie, the foremost favorable turnaround remodeling). Contrasts in their impact on remodeling have been as of late appeared among the beta-blockers.
Michel Komajda	Institut de Cardiologie, France	Double-blind randomized trials	2004	There was no gather-related contrast in unfavorable occasions amid up-titration. Withdrawal rates were 31, 30, and 30%, and genuine unfavorable occasions were 28, 29, and 34% within the combination, carvedilol, and enalapril arms. Mortality was comparable in all bunches (all-cause N=14, 14, and 14; cardiovascular N=9, 13, and 14). All-cause and cardiovascular hospitalizations happened in 26, 27, and 32%, and in 12, 16, and 22% within the combination, carvedilol and enalapril arms, individually.	The security profile was comparable in all treatment arms. In differentiate to common recognition, there was no distinction in tolerability between the ACE-I and carvedilol. This result is indeed more surprising as the tall prestudy utilizes ACE-I (65%) might have presented an inclination by selecting ACE-I tolerant patients, who were as it was exchanged from their previous ACE-I to enalapril.
Britt Kveiborg <i>et al.</i> ,	Bispebjerg University Hospital, Copenhagen, Denmark	Double-blind randomized matter	2007	Beta-blockers have appeared to make strides in survival in patients with constant heart failure. The impact of diverse eras of beta blockers has been talked about. Both metoprolol and carvedilol have illustrated advantageous impacts in placebo-controlled trials. Within The Carvedilol Or Metoprolol European Trial (COMET) two beta-blockers were compared in a double-blind randomized matter. Typically the primary coordinates comparison between metoprolol and carvedilol of long-term impact on survival in patients with incessant heart failure.	The all-cause mortality was significantly diminished with the support of carvedilol. The measurements and definition of metoprolol used in this trial have caused talk about, and it has been addressed whether a comparative beta1-blockade is obtained within the two mediation bunches. At this time there's an uncertain wrangle about as to whether carvedilol may be a predominant beta-blocker or whether contrasts in beta1-blockade clarified the comes about of COMET.
Robert Neil Doughty	Auckland Hospital Support Building, Park Road, Auckland, New Zealand	Control Trial	2007	Carvedilol may be a beta-adrenergic adversary with vasodilatory properties (alpha1-antagonism), which has been broadly assessed within the treatment of patients with heart failure. In patients with constant heart failure, carvedilol moves forward left-ventricular (LV) launch division over 6 to 12 months of treatment and weakens LV rebuilding. Large-scale randomized, fake treatment controlled trials including more than 4000 patients with constant heart failure have illustrated that carvedilol moves forward survival and decreases hospitalizations.	Comparative thinks about metoprolol in patients with heart failure have recommended that carvedilol may be related to a more prominent survival advantage even though contrasts within the arrangement of metoprolol have cleared out vulnerability in this zone. Carvedilol features a tall security profile and the clinical benefits show up kept up over a wide extent of patients with comorbidities such as diabetes and renal failure.
LucPoirier BPharm <i>et al.</i> ,	Clinique d'hypertension et département de pharmacie, Canada	Literature Review	2014	It remains that $\beta$ -blocking specialist with their abilities to piece the $\beta$ 1-adrenergic receptor are the drugs of choice strongly or constant cardiac ischemia's patients. They are part of patients's treatment with heart failure in expansion with a renin-angiotensin-aldosterone frame-work inhibition-based treatment.	This audit will center on the heterogeneity of the pharmacologic characteristics of $\beta$ -blockers, and we are going examine the metabolic and hemodynamic contrasts inside the $\beta$ -blocker lesson and attempt to evaluate the potential suggestions of these contrasts for ideal determination in hypertension.

Author	Origin	Method	Period	Result	Outcome
Rasmus Bølling	Aalborg University, Denmark.	Cohort Study	2014	High-dose carvedilol was associated with a lower likelihood of all-cause hospitalization (HR 0.842, 0.774-0.915) than high-dose metoprolol, whereas high-dose bisoprolol had a lower risk than high-dose metoprolol (HR 0.948, 0.850 -1.057).	Patients with heart failure that receiving high-dose carvedilol (≥50 mg daily) seem to have a lower risk of death and hospitalization from all causes, compared with other beta-blockers.
Daniele Masarone	Monaldi Hospital,Naples, Italy;	Literature Review	2021	β-Blockers are one of the four disease-modifying medicate sorts that have the most noteworthy effect on the long-term forecast of patients with HFrEF; subsequently, all universal rules prescribe the utilize of β-blockers as a first-line treatment for patients with HFrEF. Be that as it may, to date, they are underused, primarily since of the misinterpretation that hypotension and bradycardia may compound the haemodynamic status of patients with HFrEF as a result of the nearness of comorbidities dishonestly accepted to be supreme contraindications to their utilize.	It is trusted that the down to earth approach examined in this audit will permit for a appropriate dissemination of information approximately the right utilize of β-blockers and the drug-disease intelligent to attain their expanded utilize and titration, as well as for the choice of a particular operator with a see to a appropriately custom-made approach for HFrEF patients.
Yodo Tamaki	Kyoto University, Japan	Study Population	2021	Among 3817 patients without ACS included, 1512 patients gotten beta-blockers on affirmation for the ADHF inpatient record, while 2305 patients did not. The empowering comes about were that patients who gotten beta-blockers had less bronchial asthma or dementia than those who did not get beta-blockers at affirmation.	HF patients accepting beta-blocker treatment at the time of certification were related with essentially lower in-hospital mortality rates than patients with strongly decompensated heart failure.
Stefania Polalio	University of Naples, Italy	Literature Review	2021	The point of this think about was to analyze open prove on the utilize of β-blockers in HFrEF patients with the foremost common comorbidities.	β-blockers are disease-modifying drugs that have important effects in the long-term therapy of patients with HFrEF. These drugs are first-line drugs in close proximity to left ventricular dysfunction which must be titrated to the largest sustained dose in order for us to experience their full prognostic benefit. Beta-blockers are still underutilized in patients with HFrEF because they are affected by complex comorbidities, including contraindications.

**Pharmacological Effect of β-Blocker Drugs**

**Table 2: The Pharmacological Effect of β-Blocker Drugs**

	Bisoprolol	Bucindolol	Carvedilol	Metoprolol	Nebivolol	Acebutolol	Atenolol	Labetolol	Pindolol	Nadolol	Sotalol	Timolol
<b>Anti-oxidant effect</b>			+		+							
<b>Anti-apoptotic</b>			+		+							
<b>Inhibit endothelin</b>			+									
<b>Intrinsic sympathomimetic activity</b>		+				+			+			
<b>α<sub>1</sub> blockade</b>		+	+									
<b>β<sub>1</sub> blockade</b>	+	+	+	+	+	+	+	+	+	+	+	+
<b>β<sub>2</sub> blockade</b>		+	+			+	+	+				

The β-blockers recognized for HF treatment differentiate astonishingly (Table 2). Metoprolol and bisoprolol are β-1-specific administrators. Nebivolol to boot a β-1 particular calm but has additional vasodilating properties, conceivably related to endothelial nitric oxide generation. In separate, carvedilol pieces not because it were the β-1 receptor, but additionally the β-2 and alpha-1 adrenoceptors. In

development, carvedilol has anti-oxidative and anti-endothelin properties. The address rises whether the assorted adrenergic blocking works out of these β-blockers are germane to their valuable effect on HF. One basic heading to answer that addresses without the necessity for colossal controlled think almost concerns their individual adjusting effect on cardiac remodeling [9].

## 5. RESULT

Carvedilol is as favored beta-blocker in cardiac remodeling and heart failure. Carvedilol secures better against cardiac remodeling and following heart failure than more particular beta-adrenergic blockers. The disputes for this consolidate its comprehensive blocking of all 3 adrenergic receptors, as appeared over, and its anti-oxidant, anti- apoptotic, and anti-endothelin impacts. Compared to metoprolol succinate, carvedilol at estimations that drove to comparable heart rate diminishments started through and through more essential changes of cardiac work in mutts with pacing-induced heart failure and extended renal, hepatic, and skeletal muscle circulatory system [25-28]. In extension, it moved forward myocardial glucose take-up (giving more better essentialness conservation) compared to metoprolol and antagonized the response to exogenous norepinephrine to a more conspicuous degree than metoprolol succinate [29-33].

In heart failure patients carvedilol applies a more powerful anti-adrenergic impact than metoprolol amid push [34, 35]. This may mostly clarify the way better anti-remodeling properties of carvedilol were watched in most thinks about which compared it to beta-1 specific blocking operators such as metoprolol. Sanderson *et al.*, watched a more prominent diminish in LV volumes with carvedilol than with metoprolol in heart failure patients [36]. Metra and colleagues detailed an altogether more noteworthy increment in LV discharge division after 1-year treatment with carvedilol compared to metoprolol [37]. In differentiation, Kucin *et al.*, found comparable enhancements in LV discharge division [38]. Be that as it may, this was a little considered over a shorter period. At last, in a meta-analysis counting all accessible controlled trials, Packer and colleagues too found an altogether more tnoteworthy increment in LV discharges division with carvedilol than with metoprolol [39].

Suggestions for further research are cohort studies of sufficient duration to compare the long-term effects of carvedilol on morbidity and survival compared to selective beta-1 blockade. Because current studies are not available to demonstrate sufficient size or sufficient duration to allow comparison of the long-term effects of carvedilol.

## 6. CONCLUSION

$\beta$ -Blockers have for the most part illustrated littler diminishments in cardiovascular occasions, compared with other antihypertensive classes, in spite of comparable decreases in blood weight. This may be due to the incapability of conventional  $\beta$ -blockers, such as atenolol, in lessening central aortic weight, a solid, autonomous indicator of the cardiovascular result. Be that as it may, the  $\beta$ -blocker course is heterogeneous, and a few more up-to-date  $\beta$ -blockers, which display vasodilatory impacts autonomous of  $\beta$ -blockade, give

advantageous impacts on blood vessel solidness and endothelial brokenness, which may lead to decreases in central aortic weight and enhancements in clinical results. For case, the vasodilating  $\beta$ -blocker nebivolol appeared to progress lower arm bloodstream and blood vessel solidness and, in an expansive clinical consider, to altogether decrease horribleness and mortality, autonomous of cleared out ventricular launch division, among patients with unremitting heart failure.

There's adequate proof from pre-clinical and clinical ponders that carvedilol has more articulated anti- remodeling impacts in heart failure than specific  $\beta$ -blocking operators, more particularly the  $\beta$ -1 particular blocking drugs metoprolol and bisoprolol. The noteworthy distinction inadequacy is due to a combination of components, counting the comprehensive bar of all 3 adrenergic receptors by carvedilol, and its anti-oxidative, anti-apoptotic and anti-endothelin effects. As a result, carvedilol was driven to a noteworthy and clinically significant change in survival, superior well- being, less unused onset diabetes, and essentially fewer vascular occasions counting MI and stroke. Taken together, these come about clearly indicate that carvedilol is the favored  $\beta$ -blocker in the treatment of incessant heart failure.

But, because this drug is not halal drug so that still there are some adverse effects reported. The most common adverse effect associated with carvedilol is related to undesired, excessive hypotension secondary to its vasodilating properties. These include dizziness, lightheadedness, fatigue, and headaches. Other adverse effects are related to the beta- blocking properties, including dyspnea, bronchospasm, bradycardia, malaise, and asthenia. Additional symptoms of diarrhea, weight gain, headache, depression, impotence, and renal insufficiency also have correlations with carvedilol administration [40].

### Suggestion

Consuming halal is a command of Allah for Muslim. According to the Q.S. Al-Baqarah verses 168 and 172. Using halal products is not only in food, but halal has now developed in medical science which is commonly called halal pharmacy. Halal can be interpreted as things that are permissible and can be done because they are free or not bound by the provisions that prohibit them. The things that determine halal are halal in substance, halal in processing it, halal in storage, halal in presentation or transportation, and halal way of obtaining it. In Indonesia, because the majority of the population is Muslim, there should be a halal substitute medicine that is correct for HF sufferers.

"Indeed, Allah has not made healing for you in what he has forbidden" (Narrated by Bukhari). Therefore, the authors hope that halal drugs will be

developed to reduce the adverse effects of illicit drugs on the body and soul of heart failure patients.

There are many medicines that Allah (SWT) has described as a cure for all diseases, such as black cummin. In addition, honey, bidara leaves, grapes, figs and other fruits also have a good effect on the physical and mental health of heart failure patients.

In addition to good treatment, Rasulullah also ordered us to give charity. Because charity can prolong life, Rasulullah SAW said, "Alms to the poor only get the reward of charity, while alms to relatives contain two virtues, namely charity and connecting kinship ties" (HR Tirmidhi, Abu Dawud, Nasa'i, and Ibn Majah).

## ACKNOWLEDGMENT

The author declares there is no conflict of interest.

## REFERENCES

1. Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *New England Journal of Medicine*, 334(21), 1349-1355.
2. CIBIS II Investigators and Committees. (1999). The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. *Lancet*, 353, 9-13.
3. Hjalmarson, A., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjeksus, J., ... & Dahle, M. (1999). Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). *Lancet*, 353(9169), 2001-2007.
4. Packer, M., Coats, A. J., Fowler, M. B., Katus, H. A., Krum, H., & Mohacsi, P. (2001). for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group: Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med*, 344, 1651-1658.
5. Capricorn Investigators. (2001). Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *The Lancet*, 357(9266), 1385-1390.
6. Flather, M. D., Shibata, M. C., Coats, A. J., Van Veldhuisen, D. J., Parkhomenko, A., Borbola, J., ... & Poole-Wilson, P. A. (2005). Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *European heart journal*, 26(3), 215-225.
7. Hunt, S. A., Abraham, W. T., ... & Chin, M. H. (2005). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. *Circulation*, 112, e154-235.
8. Swedberg, K., Cleland, J., Dargie, H., Drexler, H., Follath, F., Komajda, M., ... & Remme, W. J. (2005). Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005) The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. *European heart journal*, 26(11), 1115-1140.
9. Cohn, J. N. (2004). Remodeling as an end-point in heart failure therapy. *Cardiovascular drugs and therapy*, 18(1), 7-8.
10. Remme, W. J. (2003). Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy. *Cardiovascular drugs and therapy*, 17(4), 349-360.
11. Yamazaki, T., Komuro, I., Kudoh, S., Zou, Y., Nagai, R., Aikawa, R., ... & Yazaki, Y. (1998). Role of ion channels and exchangers in mechanical stretch-induced cardiomyocyte hypertrophy. *Circulation research*, 82(4), 430-437.
12. Ungureanu-Longrois, D., Balligand, J. L., Simmons, W. W., Okada, I., Kobzik, L., Lowenstein, C. J., ... & Smith, T. W. (1995). Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to  $\beta$ -adrenergic agonists. *Circulation research*, 77(3), 494-502.
13. Li, X., Moody, M. R., Engel, D., Walker, S., Clubb Jr, F. J., Sivasubramanian, N., ... & Reid, M. B. (2000). Cardiac-specific overexpression of tumor necrosis factor- $\alpha$  causes oxidative stress and contractile dysfunction in mouse diaphragm. *Circulation*, 102(14), 1690-1696.
14. Francis, G. S., Benedict, C., Johnstone, D. E., Kirlin, P. C., Nicklas, J., Liang, C. S., ... & Yusuf, S. F. (1990). Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). *Circulation*, 82(5), 1724-1729.
15. Mann, D. L., Kent, R. L., Parsons, B., & Cooper 4th, G. (1992). Adrenergic effects on the biology of the adult mammalian cardiocyte. *Circulation*, 85(2), 790-804.
16. Communal, C., Singh, K., Pimentel, D. R., & Colucci, W. S. (1998). Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the  $\beta$ -adrenergic pathway. *Circulation*, 98(13), 1329-1334.
17. Tan, L. B., Benjamin, I. J., & Clark, W. A. (1992).  $\beta$  Adrenergic receptor desensitisation may serve a cardioprotective role. *Cardiovascular research*, 26(6), 608-614.
18. Prabhu, S. D., Wang, G., Luo, J., Gu, Y., Ping, P., & Chandrasekar, B. (2003).  $\beta$ -Adrenergic receptor blockade modulates Bcl-XS expression and reduces apoptosis in failing myocardium. *Journal of molecular and cellular cardiology*, 35(5), 483-493.

19. Du, X. J., Autelitano, D., Dilley, R. J., Wang, B., Dart, A. M., & Woodcock, E. A. (2000).  $\beta_2$ -adrenergic overexpression exacerbates development of heart failure after aortic stenosis. *Circulation*, 101, 71-77.
20. Billman, G. E., Castillo, L. C., Hensley, J., Hohl, C. M., & Altschuld, R. A. (1997).  $\beta_2$ -Adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to  $\beta_2$ -adrenergic stimulation in animals susceptible to sudden death. *Circulation*, 96(6), 1914-1922.
21. Molenaar, P., Christ, T., Ravens, U., & Kaumann, A. (2006). Carvedilol blocks  $\beta_2$ -more than  $\beta_1$ -adrenoceptors in human heart. *Cardiovascular research*, 69(1), 128-139.
22. Kindermann, M., Maack, C., Schaller, S., Finkler, N., Schmidt, K. I., L  er, S., ... & B  hm, M. (2004). Carvedilol but not metoprolol reduces  $\beta$ -adrenergic responsiveness after complete elimination from plasma in vivo. *Circulation*, 109(25), 3182-3190.
23. Zhao, Q., Wu, T. G., Jiang, Z. F., Chen, G. W., Lin, Y., & Wang, L. X. (2007). Effect of  $\beta$ -blockers on  $\beta_3$ -adrenoceptor expression in chronic heart failure. *Cardiovascular drugs and therapy*, 21(2), 85-90.
24. Wisler, J. W., DeWire, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., ... & Lefkowitz, R. J. (2007). A unique mechanism of  $\beta$ -blocker action: carvedilol stimulates  $\beta$ -arrestin signaling. *Proceedings of the National Academy of Sciences*, 104(42), 16657-16662.
25. Nikolaidis, L. A., Poornima, I., Parikh, P., Magovern, M., Shen, Y. T., & Shannon, R. P. (2006). The effects of combined versus selective adrenergic blockade on left ventricular and systemic hemodynamics, myocardial substrate preference, and regional perfusion in conscious dogs with dilated cardiomyopathy. *Journal of the American College of Cardiology*, 47(9), 1871-1881.
26. Hanada, K., Asari, K., Saito, M., Kawana, J. I., Mita, M., & Ogata, H. (2008). Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. *European journal of pharmacology*, 589(1-3), 194-200.
27. Lai, K. B., Sanderson, J. E., & Yu, C. M. (2009). Suppression of Collagen Production in Norepinephrine Stimulated Cardiac Fibroblasts Culture: Differential Effect of  $\alpha$  and  $\beta$ -Adrenoreceptor Antagonism. *Cardiovascular drugs and therapy*, 23(4), 271-280.
28. Batenburg, W. W., Van Esch, J. H., Garrelds, I. M., Jorde, U., Lamers, J. M., Dekkers, D. H., ... & Danser, A. J. (2006). Carvedilol-induced antagonism of angiotensin II: a matter of  $\alpha_1$ -adrenoceptor blockade. *Journal of hypertension*, 24(7), 1355-1363.
29. Bartholomeu, J. B., Vanzelli, A. S., Rolim, N. P., Ferreira, J. C., Bechara, L. R., Tanaka, L. Y., ... & Brum, P. C. (2008). Intracellular mechanisms of specific  $\beta$ -adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure. *Journal of molecular and cellular cardiology*, 45(2), 240-249.
30. Wang, R., Miura, T., Harada, N., Kametani, R., Shibuya, M., Fukagawa, Y., ... & Matsuzaki, M. (2006). Pleiotropic effects of the  $\beta$ -adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes. *Journal of Pharmacology and Experimental Therapeutics*, 318(1), 45-52.
31. Kametani, R., Miura, T., Harada, N., Shibuya, M., Wang, R., Tan, H., ... & Matsuzaki, M. (2006). Carvedilol inhibits mitochondrial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria. *Circulation Journal*, 70(3), 321-326.
32. Brixius, K., Lu, R., Boelck, B., Grafweg, S., Hoyer, F., Pott, C., ... & Schwinger, R. H. (2007). Chronic treatment with carvedilol improves  $\text{Ca}^{2+}$ -dependent ATP consumption in triton X-skinned fiber preparations of human myocardium. *Journal of Pharmacology and Experimental Therapeutics*, 322(1), 222-227.
33. Sun, Y. L., Hu, S. J., Wang, L. H., Hu, Y., & Zhou, J. Y. (2005). Effect of  $\beta$ -blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. *Chest*, 128(3), 1812-1821.
34. Kohno, T., Yoshikawa, T., Yoshizawa, A., Nakamura, I., Anzai, T., Satoh, T., & Ogawa, S. (2005). Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. *Cardiovascular drugs and therapy*, 19(5), 347-355.
35. Azevedo, E. R., Kubo, T., Mak, S., Al-Hesayen, A., Schofield, A., Allan, R., ... & Parker, J. D. (2001). Nonselective versus selective  $\beta$ -adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. *Circulation*, 104(18), 2194-2199.
36. Sanderson, J. E., Chan, S. K., Yip, G., Yeung, L. Y., Chan, K. W., Raymond, K., & Woo, K. S. (1999). Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. *Journal of the American College of Cardiology*, 34(5), 1522-1528.
37. Metra, M., Giubbini, R., Nodari, S., Boldi, E., Modena, M. G., & Cas, L. D. (2000). Differential effects of  $\beta$ -blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. *Circulation*, 102(5), 546-551.
38. Kukin, M. L., Kalman, J., Charney, R. H., Levy, D. K., Buchholz-Varley, C., Ocampo, O. N., & Eng, C. (1999). Prospective, randomized comparison of effect of long-term treatment with metoprolol or

- carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. *Circulation*, 99(20), 2645-2651.
39. Packer, M., Antonopoulos, G. V., Berlin, J. A., Chittams, J., Konstam, M. A., & Udelson, J. E. (2001). Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. *American heart journal*, 141(6), 899-907.
40. Dunn, C. J., Lea, A. P., & Wagstaff, A. J. (1997). Carvedilol: A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. *Drugs*, 54(1), 161-85.